| abstract |
The object of the invention is the use of compounds of the formula I wherein R.sup.1 is n. is phenyl-C.sub.1-C.sub.4-alkyl, optionally substituted on the benzene ring by C.sub.1-C.sub.4-alkyl; C 1-6 -alkoxy or halogen, or naphthyl-C 1-6 alkyl, C 1-6 alkyl, R 5, c. n. is hydrogen or a group forming a biologically cleavable ester; is hydrogen or a group forming a biologically cleavable ester, wherein the biologically cleavable ester forming group is C.sub.1-C.sub.4 alkyl group; phenyl or phenyl-C 1-6 alkyl-C 1-6 alkyl which may be substituted on the benzene core by C 1-6 alkyl. -alkyl or C 3-6 alkylene chain bonded to two adjacent benzene ring atoms, especially phenyl, benzyl or indanyl; dioxolanylmethyl, optionally substituted on the dioxolane ring by C.sub.1-C.sub.4-alkyl, especially (2,2-dimethyl-1,3-dioxolan-4-yl) methyl; and C.sub.2-C.sub.6-alkanoyloxymethyl optionally substituted on oxymethyl with C.sub.1-C.sub.4-alkyl; and physiologically tolerable acid addition salts of the formula I, for the preparation of pharmaceutical compositions for the prophylaxis and / or treatment of heart damage, in particular of the human myocardium caused by cardiotoxic doses of cytostatically effective antibiotics selected from the group consisting of anthracycline and mitoxantrone. |